Breaking News Instant updates and real-time market news.

VSAR

Versartis

$21.60

-0.25 (-1.14%)

05:49
09/22/17
09/22
05:49
09/22/17
05:49

Versartis downgraded to Market Perform, price target slashed to $3 at Cowen

Cowen analyst Ken Cacciatore downgraded Versartis to Market Perform from Outperform and slashed its price target to $3 from $45 following the VELOCITY trial failure. The analyst removed somavaratan from his valuation and said shares will now trade based on proforma cash levels.

VSAR Versartis
$21.60

-0.25 (-1.14%)

09/08/17
PIPR
09/08/17
NO CHANGE
Target $26
PIPR
Overweight
Piper says own Versartis into Phase III data later this month
Piper Jaffray analyst Edward Tenthoff recommends owning shares of Versartis into the Phase III Velocity data on somavaratan in pediatric growth hormone deficiency due by the end of September. The analyst continues to expect somavaratan to demonstrate non-inferior height velocity within the 2cm lower confidence interval to daily growth hormone at one year. Even if somavaratan produces numerically lower height velocity to daily growth hormone, this would be a win since less frequent dosing should result in higher real-world compliance and growth, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Versartis with a $26 price target.
09/22/17
PIPR
09/22/17
DOWNGRADE
Target $4
PIPR
Neutral
Versartis downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Versartis to Neutral citing an uncertain future for somavaratan after the Phase III Velocity trial patients missed non-inferior height velocity. Should Versartis conduct another Phase III pediatric growth hormone deficiency trial, the analyst expects delayed approval timelines by at least two years. He cut his price target for the shares to $4 from $26.
09/22/17
LEHM
09/22/17
DOWNGRADE
Target $4
LEHM
Underweight
Versartis downgraded to Underweight from Overweight at Barclays
Barclays analyst Geoff Meacham double downgraded Versartis to Underweight from Overweight and cut his price target for the shares to $4 from $28 after the Phase 3 Velocity trial of somavaratan missed its primary endpoint. The analyst does not see a path forward for the pediatric program and sees minimal residual value to the adult program. Piper Jafray this morning also downgraded Versartis.
09/22/17
WELS
09/22/17
NO CHANGE
Target $51
WELS
Outperform
Versartis failure bodes well for Ascendis Pharma, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Ascendis Pharma (ASND) after its competitor Versartis (VSAR) announced last night that its long-acting recombinant human growth hormone, somavaratan, failed to meet the primary endpoint of non-inferiority in a Phase 3 study in pediatric growth hormone deficiency. The analyst continues to see a "high likelihood of success" for Ascendis Pharma's unmodified TransCon GH, which he says appears superior to both somavaratan and short acting growth hormone. Birchenough has a $51 price target on Ascendis shares. The stock last night in after-hours trading jumped 42%, or $11.66, to $39.40.

TODAY'S FREE FLY STORIES

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

, AVGO

Broadcom

$248.62

-1 (-0.40%)

13:36
02/22/18
02/22
13:36
02/22/18
13:36
Hot Stocks
Qualcomm announces letter sent to stockholders, video posted to site »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

AVGO

Broadcom

$248.62

-1 (-0.40%)

NXPI

NXP Semiconductors

$125.60

0.04 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

AUDVF

Audi AG

, VLKAY

Volkswagen

$40.43

-0.57 (-1.39%)

13:35
02/22/18
02/22
13:35
02/22/18
13:35
Periodicals
German prosecutors raid homes of former Audi board members, AFP says »

German prosecutors said…

AUDVF

Audi AG

VLKAY

Volkswagen

$40.43

-0.57 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$12.57

-0.0933 (-0.74%)

13:25
02/22/18
02/22
13:25
02/22/18
13:25
Conference/Events
Barrick Gold to host investor day »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

13:25
02/22/18
02/22
13:25
02/22/18
13:25
Conference/Events
Morgan Stanley insurance analysts to hold an analyst/industry conference call »

Analysts host Charles…

13:20
02/22/18
02/22
13:20
02/22/18
13:20
General news
Treasury's $29 B 7-year sale was a disappointment »

Treasury's $29 B…

CSGP

CoStar Group

$352.11

0.27 (0.08%)

13:18
02/22/18
02/22
13:18
02/22/18
13:18
Recommendations
CoStar Group analyst commentary  »

Stephens would be buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 23

    May

$NSD

NASDAQ Market Internals

13:17
02/22/18
02/22
13:17
02/22/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
02/22/18
02/22
13:16
02/22/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
02/22/18
02/22
13:15
02/22/18
13:15
General news
Treasury Action: yields kicked up from lows »

Treasury Action: yields…

ALKS

Alkermes

$63.19

-1.56 (-2.41%)

, NKTR

Nektar

$86.45

3 (3.60%)

13:11
02/22/18
02/22
13:11
02/22/18
13:11
Hot Stocks
Analyst cuts Alkermes rating as cancer drug seems less effective than competitor »

Shares of Alkermes (ALKS)…

ALKS

Alkermes

$63.19

-1.56 (-2.41%)

NKTR

Nektar

$86.45

3 (3.60%)

BMY

Bristol-Myers

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 05

    Mar

  • 08

    Mar

  • 04

    Apr

  • 03

    May

CIDM

Cinedigm

$1.25

0.0201 (1.63%)

13:10
02/22/18
02/22
13:10
02/22/18
13:10
Hot Stocks
Cinedigm acquires North American rights to 'Class Rank' »

Cinedigm Corp has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

FB

Facebook

$177.91

1.9 (1.08%)

13:09
02/22/18
02/22
13:09
02/22/18
13:09
Technical Analysis
Technical Take: Facebook trades near session lows »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 18

    Mar

HPQ

HP Inc.

$21.52

0.345 (1.63%)

, LNVGY

Lenovo

$10.15

-0.01 (-0.10%)

13:09
02/22/18
02/22
13:09
02/22/18
13:09
Earnings
On The Fly: What to watch for in HP Inc.'s earnings report »

HP Inc. (HPQ) is…

HPQ

HP Inc.

$21.52

0.345 (1.63%)

LNVGY

Lenovo

$10.15

-0.01 (-0.10%)

AAPL

Apple

$171.07

-0.78 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 26

    Feb

  • 24

    Apr

  • 30

    May

MIC

Macquarie Infrastructure

$39.09

-24.53 (-38.56%)

13:09
02/22/18
02/22
13:09
02/22/18
13:09
Recommendations
Macquarie Infrastructure analyst commentary  »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BAMXY

BMW Group

13:05
02/22/18
02/22
13:05
02/22/18
13:05
Hot Stocks
BMW to pay $2.2M to settle DOJ claims of SCRA violations »

The Justice Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
02/22/18
02/22
13:05
02/22/18
13:05
General news
7-Yr Note Auction Coupon Rate data reported »

7-Yr Note Auction Coupon…

13:05
02/22/18
02/22
13:05
02/22/18
13:05
General news
7-Yr Note Auction Total Amount data reported »

7-Yr Note Auction Total…

W

Wayfair

$74.55

-21.14 (-22.09%)

13:05
02/22/18
02/22
13:05
02/22/18
13:05
Recommendations
Wayfair analyst commentary  »

Citi trims Wayfair target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EAT

Brinker

13:05
02/22/18
02/22
13:05
02/22/18
13:05
Options
Brinker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$33.03

-0.95 (-2.80%)

, VIA

Viacom

$38.35

-1.15 (-2.91%)

13:04
02/22/18
02/22
13:04
02/22/18
13:04
Hot Stocks
SEGA, Paramount announce agreement to co-produce Sonic the Hedgehog feature film »

SEGA Holdings announced…

VIAB

Viacom

$33.03

-0.95 (-2.80%)

VIA

Viacom

$38.35

-1.15 (-2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

GOOGL

Alphabet Class A

$1,113.75

10.16 (0.92%)

12:55
02/22/18
02/22
12:55
02/22/18
12:55
Technical Analysis
Technical Take: Alphabet Class A moves lower in intraday rounding pattern »

The shares have dropped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DPS

Dr Pepper Snapple

$115.28

-0.1 (-0.09%)

12:55
02/22/18
02/22
12:55
02/22/18
12:55
Options
Dr Pepper Snapple put volume heavy and directionally bearish »

Bearish flow noted in Dr…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
02/22/18
02/22
12:55
02/22/18
12:55
General news
Treasury Option Action: a rash of put buying »

Treasury Option Action: a…

12:55
02/22/18
02/22
12:55
02/22/18
12:55
Conference/Events
CFA Society of Milwaukee to hold a luncheon discussion »

Bill Stone, CMT of PNC…

12:55
02/22/18
02/22
12:55
02/22/18
12:55
Conference/Events
STAT Plus to hold webinar »

STAT Senior Science…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.